Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04272554 · ClinicalTrials.gov registry record
AAV Gene Therapy Screening/Observational Protocol (ECLIPSE)
A clinical trial of Hemophilia B and Blood Coagulation Disorder, sponsored by Spur Therapeutics.
- Completed
- Registry status
- 37
- Enrollment target
- 20
- Study locations
NCT04272554: Completed study of Hemophilia B and Blood Coagulation Disorder, sponsored by Spur Therapeutics.
NCT04272554 is a study of Hemophilia B and Blood Coagulation Disorder that has completed, run by Spur Therapeutics. The registered enrollment target is 37 participants, below the 95-participant average among 20 other Hemophilia B trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04272554, a study of Hemophilia B and Blood Coagulation Disorder, has completed, sponsored by Spur Therapeutics.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
- 20
- Study locations
Study Summary
Freeline is developing adeno-associated virus (AAV) vector based gene therapies for a number of diseases and is actively advancing a programme in Haemophilia B (HB). This study aims to collect prospective data to characterise bleeding events and Factor IX (FIX) concentrate consumption in HB patients that can be used as baseline for participants who elect to participate in a subsequent Freeline gene therapy study. The study will also screen participants for antibodies to a novel AAV vector to assess their suitability for inclusion in a Freeline gene therapy treatment study.
Primary Outcome
Bleeding episode data recorded during the study
Conditions Studied
Study Locations (20)
Other
- Royal Children's Hospital, Parkville - Melbourne
- The Alfred Hospital - Melbourne
- Calvary Mater Hospital - Newcastle
California
- Children's Hospital of Los Angeles - Los Angeles
- University of California - Davis - Sacramento
North Carolina
- University of North Carolina (UNC) - Chapel Hill
- East Carolina University - Greenville
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- Nationwide Childrens Hospital - Columbus
Tennessee
- St. Jude Children's Research Hospital - Memphis
- Vanderbilt University Medical Center - Nashville
Arizona
- Phoenix Childrens Hospital - Phoenix
Florida
- University of South Florida - Tampa
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2020-02-14 |
| Est. Completion | 2022-10-10 |
What the finished NCT04272554 record still lists
NCT04272554 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 95-participant average among 20 other Hemophilia B trials with a reported enrollment target (61% lower).
The record links to 4 conditions, with Hemophilia B appearing as the primary indexed condition, and to 0 interventions.
NCT04272554 names 20 study sites across 14 states, led by Other, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04272554 about?
NCT04272554 is a clinical study titled "AAV Gene Therapy Screening/Observational Protocol (ECLIPSE)". Freeline is developing adeno-associated virus (AAV) vector based gene therapies for a number of diseases and is actively advancing a programme in Haemophilia B (HB). This study aims to collect prospective data to characterise bleeding events and Factor IX (FIX) concentrate consumption in HB patients...
What is the current status of trial NCT04272554?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2020-02-14. Estimated completion is 2022-10-10.
What conditions does trial NCT04272554 study?
This clinical trial studies the following conditions: Hemophilia B, Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited, Haematologic Disease.
Who is sponsoring clinical trial NCT04272554?
This trial is sponsored by Spur Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04272554 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04272554's enrollment target sits among peer trials
37 10th of 20 higher than 11 of 20 other Hemophilia B trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia B trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
RECRUITING · Phase 3
-
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
RECRUITING · Phase 1
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
RECRUITING · Phase 3
-
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI